Uncertainty Minimization for Personalized Federated Semi-Supervised Learning

Since federated learning (FL) has been introduced as a decentralized learning technique with privacy preservation, statistical heterogeneity of distributed data stays the main obstacle to achieve robust performance and stable convergence in FL applications. Model personalization methods have been studied to overcome this problem. However, existing approaches are mainly under the prerequisite of fully labeled data, which is unrealistic in practice due to the requirement of expertise. The primary issue caused by partial-labeled condition is that, clients with deficient labeled data can suffer from unfair performance gain because they lack adequate insights of local distribution to customize the global model. To tackle this problem, 1) we propose a novel personalized semi-supervised learning paradigm which allows partial-labeled or unlabeled clients to seek labeling assistance from data-related clients (helper agents), thus to enhance their perception of local data; 2) based on this paradigm, we design an uncertainty-based data-relation metric to ensure that selected helpers can provide trustworthy pseudo labels instead of misleading the local training; 3) to mitigate the network overload introduced by helper searching, we further develop a helper selection protocol to achieve efficient communication with negligible performance sacrifice. Experiments show that our proposed method can obtain superior performance and more stable convergence than other related works with partial labeled data, especially in highly heterogeneous setting.Comment: 11 page

IL28B is associated with outcomes of chronic HBV infection

Purpose The role of IL28B gene variants and expression in hepatitis B virus (HBV) infections are not well understood. Here, we evaluated whether IL28B gene expression and rs12979860 variations are associated with HBV outcomes. Materials and Methods IL28B genetic variations (rs12979860) were genotyped by pyrosequencing of DNA samples from 137 individuals with chronic HBV infection [50 inactive carriers (IC), 34 chronic hepatitis B (CHB), 27 cirrhosis, 26 hepatocellular carcinoma (HCC)], and 19 healthy controls. IL28A/B mRNA expression in peripheral blood mononuclear cells was determined by qRT-PCR, and serum IL28B protein was measured by ELISA. Results Patients with IL28B C/C genotype had greater IL28A/B mRNA expression and higher IL28B protein levels than C/T patients. Within the various disease stages, compared to IC and healthy controls, IL28B expression was reduced in the CHB, cirrhosis, and HCC cohorts (CHB vs. IC, p=0.02; cirrhosis vs. IC, p=0.01; HCC vs. IC, p=0.001; CHB vs. controls, p&#60;0.01; cirrhosis vs. controls, p&#60;0.01; HCC vs. controls, p&#60;0.01). When stratified with respect to serum HBV markers in the IC and CHB cohorts, IL28B mRNA and protein levels were higher in HBeAg-positive than negative individuals (p=0.01). Logistic regression analysis revealed that factors associated with high IL28B protein levels were C/C versus C/T genotype [p=0.016, odds ratio (OR)=0.25, 95% confidence interval (CI)=0.08-0.78], high alanine aminotransferase values (p&#60;0.001, OR=8.02, 95% CI=2.64-24.4), and the IC stage of HBV infection (p&#60;0.001). Conclusion Our data suggest that IL28B genetic variations may play an important role in long-term development of disease in chronic HBV infections.</p

IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population

&lt;p&gt;&lt;b&gt;Background:&lt;/b&gt; The interleukin-28B gene (IL28B) locus has been associated with host resistance to hepatitis C virus (HCV) infection and response to PEG-IFN/RBV treatment in western populations. This study was to determine whether this gene variant is also associated with spontaneous clearance of HCV infection, treatment response and IL-28B protein production in Chinese patients.&lt;/p&gt; &lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; We genotyped IL28B genetic variations (rs12980275, rs8103142, rs8099917 and rs12979860) by pyrosequencing DNA samples from cohorts consisting of 529 subjects with persistent HCV infection, 196 subjects who cleared the infection, 171 healthy individuals and 235 chronic HCV patients underwent IFN/RBV treatment. The expression of IL-28B were measured by ELISA and RT-PCR.&lt;/p&gt; &lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; We found that the four IL28B variants were in complete linkage disequilibrium (r2 = 0.97–0.98). The rs12979860 CC genotype was strongly associated with spontaneously HCV clearance and successful IFN/RBV treatment compared to the CT/TT. IL-28B levels in persistent HCV patients were significantly lower than subjects who spontaneously resolved HCV and healthy controls and were also associated with high levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). IL-28B levels were also significantly lower in individuals carrying T alleles than CC homozygous.&lt;/p&gt; &lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; Thus, the rs12979860-CC variant upstream of IL28B gene is associated with spontaneous clearance of HCV, susceptible to IFN/RBV treatment and increased IL-28B levels in this Chinese population.&lt;/p&gt

Severe anemia is associated with increased short-term and long-term mortality in patients hospitalized with cirrhosis

Introduction and Objectives: The relationship between anemia and the outcome of patients with cirrhosis is not completely clear. Therefore, we performed this large-scale epidemiological study to investigate the prevalence and severity of anemia in patients with cirrhosis and acute decompensation or liver injury and how anemia impacts short-term and long-term outcomes. Patients and Methods: Patients with cirrhosis and acute decompensation (AD) or acute liver injury (ALI) were enrolled in the Chinese AcuTe on CHronic LIver FailurE (CATCH-LIFE) studies, which consisted of two large, multicenter, prospective, observational cohorts between January 2015 and December 2016 and July 2018 and January 2019. We conducted data analysis on the prevalence of anemia and determined the relationship between anemia and prognosis. Results: Among 1979 patients, 1389 (70.2%) had anemia, among whom 599 (41.3%) had mild anemia, 595 (15.8%) had moderate anemia and 195 (2.4%) had severe anemia. A linear association between hemoglobin level and 90-day or 1-year LT-free mortality was shown, and a 10 g/L decrease in hemoglobin level was associated with a 6.8% extra risk of 90-day death and a 5.7% extra risk of 1-year death. Severe anemia was an independent risk factor for 90-day [HR=1.649 (1.100, 2.473), p=0.016] and 1-year LT-free mortality [HR=1.610 (1.159, 2.238), p=0.005]. Multinomial logistic regression analysis further identified that severe anemia was significantly associated with post-28-day mortality but not within-28-day mortality. Conclusions: Anemia is common in patients with cirrhosis admitted for acute events. Severe anemia was associated with poor 90-day and 1-year prognoses in these patients

Baseline characteristics of the patients treated with IFN/RBV.

*<p>Information of HCV genotype was unavailable for 17 patients and 4 patients who did not complete the treatment.</p

The association of rs12979860 with AST levels in chronic HCV patients.

<p>The AST levels were determined using a Synchron LX®20 autoanalyser. The AST levels were higher in patients carrying the T-allele. Data are mean±SD and representative of two experiments.</p

Factors associated with RVR and cEVR by maltivariate Logistic regression.

<p>OR (odds ratio); CI (confidence interval).</p

Characteristic of 896 study subjects.

a<p>HCV viral genotypes was avaliable for 283 individuals in the persistent group.</p>▴<p>P<0.05 and</p>#<p>P = 0.04 persistent vs clearence group;</p>#<p>P<0.05, persistent vs healthy controls;</p><p>Quantitative variables are displayed as mean and SD; HCV load are displayed as median and quartile range. ALT, AST, GGT, TG, TC (alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, triglycerides and total cholesterol).</p